Free Trial
NASDAQ:CALT

Calliditas Therapeutics AB (publ) (CALT) Stock Price, News & Analysis

Calliditas Therapeutics AB (publ) logo
$40.00 0.00 (0.00%)
As of 07/9/2025

About Calliditas Therapeutics AB (publ) Stock (NASDAQ:CALT)

Key Stats

Today's Range
$40.00
$40.00
50-Day Range
$40.00
$40.00
52-Week Range
$15.25
$43.00
Volume
N/A
Average Volume
10,339 shs
Market Capitalization
$1.19 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Calliditas Therapeutics AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

CALT Stock News Headlines

Your Bank Account Is No Longer Safe
What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.
See More Headlines

CALT Stock Analysis - Frequently Asked Questions

Calliditas Therapeutics AB (publ)'s stock was trading at $40.0001 at the beginning of 2025. Since then, CALT shares have increased by 0.0% and is now trading at $40.0001.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) issued its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.09. The company earned $52.36 million during the quarter, compared to the consensus estimate of $42.89 million. Calliditas Therapeutics AB (publ) had a negative net margin of 30.18% and a negative trailing twelve-month return on equity of 212.04%.
Read the conference call transcript
.

Calliditas Therapeutics AB (publ) (CALT) raised $179 million in an initial public offering (IPO) on Friday, June 5th 2020. The company issued 9,200,000 shares at a price of $19.50 per share. Citigroup, Jefferies and Stifel acted as the underwriters for the IPO and Carnegie was co-manager.

Shares of CALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Calliditas Therapeutics AB (publ) investors own include Advanced Micro Devices (AMD), Celsius (CELH), NIO (NIO), NVIDIA (NVDA), Reata Pharmaceuticals (RETA), Target (TGT) and Athenex (ATNX).

Company Calendar

Last Earnings
8/13/2024
Today
7/10/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CALT
CIK
1795579
Fax
N/A
Employees
180
Year Founded
2004

Profitability

EPS (Trailing Twelve Months)
($1.85)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$43.96 million
Net Margins
-30.18%
Pretax Margin
-29.40%
Return on Equity
-212.04%
Return on Assets
-27.96%

Debt

Debt-to-Equity Ratio
9.44
Current Ratio
2.69
Quick Ratio
2.59

Sales & Book Value

Annual Sales
$1.60 billion
Price / Sales
0.74
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.06 per share
Price / Book
37.74

Miscellaneous

Outstanding Shares
29,790,000
Free Float
29,135,000
Market Cap
$1.19 billion
Optionable
Optionable
Beta
1.77

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:CALT) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners